Stryker stock drops more than 8% after upbeat Q2 results met with broad selling pressure
Stryker Corporation (SYK) plunged 8.02% after reporting strong second-quarter earnings with raised full-year guidance and fresh M&A activity, with sellers pressing the stock despite the fundamentally positive results. The scale and persistence of the move is reinforced by weak short- and long-term trends, with prices held below key moving averages and only limited medium-term technical support in place.
Highlights
- Stryker posted Q2 2026 organic sales growth of 9% and adjusted EPS up 17.9% to $3.69, beating consensus.
- The company raised its full-year outlook, resumed share buybacks, and completed an intravascular lithotripsy portfolio acquisition.
- Shares trade under short- and long-term averages with technicals signaling overbought momentum and a baseline price range of $293.1 to $330.72 for the coming week.
Investor skepticism grows despite upgraded outlook and robust M&A activity
Stryker reported strong results for the second quarter of 2026, posting sales of $6.59 billion reflecting 9% organic growth year-over-year. Adjusted earnings per share reached $3.69, up 17.9% from the previous year and surpassing analyst consensus estimates. The company raised its 2026 guidance for organic sales growth and adjusted EPS, resumed share repurchases, and completed the acquisition of Amplitude Vascular Systems, expanding its intravascular lithotripsy product portfolio. These positive developments were announced, though price action has remained under broader selling pressure.
Bearish trend persists as bullish signals clash with overbought readings
Stryker is trading below the 20-day moving average at $327.55 and the 200-day moving average at $343.37, but remains just above the 50-day moving average at $317.03. This moving-average positioning signals weak short- and long-term sentiment with only limited medium-term support, as the near-term ceiling is at $327.55 and immediate floor at $318.65. The longer-term trend confirmation remains bearish given the MA-50 vs MA-200 alignment. The Ichimoku Kijun at $329.51 acts as resistance above the current price. The MACD is trending positive in buy territory, but the Average Directional Index (ADX) at 12.55 indicates a lack of strong trend direction. RSI stands at 62.77 and forecasts a buy, while Stochastic RSI (87.09), Commodity Channel Index (162.57), and Bull/Bear Power (19.29) signal overbought conditions. Bull/Bear Power above zero confirms buyer dominance intraday, and the Awesome Oscillator supports the upside momentum. The stock has dropped sharply to $320.44 near the session low after a pronounced downside gap and intraday volatility at 4.86%. There is a notable divergence between bullish momentum signals and overbought oscillator readings, keeping the tone heavy following the opening gap.
Previously it was reported that Stryker was maintaining a bullish technical structure but faced caution near resistance levels amid elevated volatility. The current selloff, despite positive earnings momentum, highlights a shift to weaker trends and heightened risk, making it essential for investors to monitor potential downside if support at $318.65 fails in coming sessions.